Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: http://thinkipstrategy.com/subscribe/

 

Plavix (Clopidogrel) – Canada: Selection patents upheld by Supreme Court: Apotex v Sanofi-Synthelabo Canada (Jeremy de Beer) (ipblog.ca) (Excess Copyright) (Managing Intellectual Property) (Law360)

Risperdal (Risperidone) – US: CAFC issues opinion in generic Risperdal 180-day exclusivity litigation reversing District Court decision: Teva Pharmaceuticals USA v Leavitt (FDA Law Blog) (Law360)

Literature on SPCs (The SPC Blog)

Brazil, EU collaborate on local production of AIDS drugs in Mozambique (Intellectual Property Watch)

Australia: Senate inquiry into human gene patents (IP Down Under)

Germany: Federal Supreme Court (Bundesgerichtshof) decides on distinctiveness of composite trade mark combining name of active pharmaceutical substance with business name – Pantohexal (Class 46)

India: Impact of the probable incorporation of an additional step (of public interest) in Indian injunction jurisprudence (Intellectual Property Watch)

US: Biotech industry begins to assess likely impact of new administration (California Biotech Law Blog)

US: New administration will act quickly to jump-start stem cell research (Patent Docs)

US: Applying Bilski to Metabolite’s diagnostic claim (Patently-O)

US: CFI rules in Neurim Pharmaceuticals (1991) v OHIM, Eurim-Pharm Arzneimittel; no restitution in integrum for Neurim (Class 46)

US: International Trade Commission concludes industrial biotech patents are ‘facilitating and not stifling innovation’ (Peter Zura’s 271 Patent Blog)

Baytril () – US: Bayer files patent infringement suit against veterinary pharmaceutical company Norbrook over generic Baytril (Law360)

Linaclotide – US: Ironwood Pharmaceuticals files suit against USPTO seeking to have patent term adjustment for constipation drug extended by almost a year (Law360)

Moxatag (Amoxicillin) – US: Patent information first listed in Orange Book covering old antibiotic product Moxatag (FDA Law Blog)

Plavix (Clopidogrel) – Canada: Selection patents upheld by Supreme Court: Apotex v Sanofi-Synthelabo Canada (Jeremy de Beer) (ipblog.ca) (Excess Copyright) (Managing Intellectual Property) (Law360)

Prevacid (Lansoprazole) – US: CAFC ruling delays Teva from selling generic Prevacid until next year: Takeda Pharmaceutical Company Limited v Tap Pharmaceutical Products, Inc (non precedential) (Patent Circle) (Law360)

Risperdal (Risperidone) – US: CAFC issues opinion in generic Risperdal 180-day exclusivity litigation reversing District Court decision: Teva Pharmaceuticals USA v Leavitt (FDA Law Blog) (Law360)

Singulair () – US: Federal Judge denies Teva‘s bid to force production of privileged documents relating to Merck’s alleged fraud in obtaining Singulair patent (Law360)